Assessment of patient empowerment--a systematic review of measures von Barr, Paul J, Scholl, Isabelle, Bravo, Paulina, Faber, Marjan J, Elwyn, Glyn, McAllister, Marion

Volltext

A three-talk model for shared decision making: multistage consultation process von Elwyn, Glyn, Durand, Marie Anne, Song, Julia, Aarts, Johanna, Barr, Paul J, Berger, Zackary, Cochran, Nan, Frosch, Dominick, Galasiński, Dariusz, Gulbrandsen, Pål, Han, Paul K J, Härter, Martin, Kinnersley, Paul, Lloyd, Amy, Mishra, Manish, Perestelo-Perez, Lilisbeth, Scholl, Isabelle, Tomori, Kounosuke, Trevena, Lyndal, Witteman, Holly O, Van der Weijden, Trudy

Volltext

How I treat early-relapsing follicular lymphoma von Casulo, Carla, Barr, Paul M.

Volltext

Estimation of an inter-rater intra-class correlation coefficient that overcomes common assumption violations in the assessment of health measurement scales von Bobak, Carly A, Barr, Paul J, O'Malley, A James

Volltext

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia von Shanafelt, Tait D, Wang, Xin V, Kay, Neil E, Hanson, Curtis A, O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F, Braggio, Esteban, Leis, Jose F, Zhang, Cong C, Coutre, Steven E, Barr, Paul M, Cashen, Amanda F, Mato, Anthony R, Singh, Avina K, Mullane, Michael P, Little, Richard F, Erba, Harry, Stone, Richard M, Litzow, Mark, Tallman, Martin

Volltext

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial von Shanafelt, Tait D, Wang, Xin Victoria, Hanson, Curtis A, Paietta, Elisabeth M, O'Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F, Braggio, Esteban, Leis, Jose F, Zhang, Cong Christine, Coutre, Steven E, Barr, Paul M, Cashen, Amanda F, Mato, Anthony R, Singh, Avina K, Mullane, Michael P, Little, Richard F, Erba, Harry, Stone, Richard M, Litzow, Mark, Tallman, Martin, Kay, Neil E

Volltext

Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab von Barr, Paul M

Volltext

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab von Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.

Volltext

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study von Burger, Jan A., Barr, Paul M., Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Tedeschi, Alessandra, Bairey, Osnat, Hillmen, Peter, Coutre, Steven E., Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Simpson, David, Offner, Fritz, Moreno, Carol, Dai, Sandra, Lal, Indu, Dean, James P., Kipps, Thomas J.

Volltext

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL von Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., Byrd, John C.

Volltext

Measurement challenges in shared decision making: putting the ‘patient’ in patient‐reported measures von Barr, Paul J., Elwyn, Glyn

Volltext

Developing CollaboRATE: A fast and frugal patient-reported measure of shared decision making in clinical encounters von Elwyn, Glyn, Barr, Paul James, Grande, Stuart W, Thompson, Rachel, Walsh, Thom, Ozanne, Elissa M

Volltext

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort von Tam, Constantine S., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Jacobs, Ryan, Opat, Stephen, Barr, Paul M., Tedeschi, Alessandra, Trentin, Livio, Bannerji, Rajat, Jackson, Sharon, Kuss, Bryone J., Moreno, Carol, Szafer-Glusman, Edith, Russell, Kristin, Zhou, Cathy, Ninomoto, Joi, Dean, James P., Wierda, William G., Ghia, Paolo

Volltext

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial von Jones, Jeffrey A, Mato, Anthony R, Wierda, William G, Davids, Matthew S, Choi, Michael, Cheson, Bruce D, Furman, Richard R, Lamanna, Nicole, Barr, Paul M, Zhou, Lang, Chyla, Brenda, Salem, Ahmed Hamed, Verdugo, Maria, Humerickhouse, Rod A, Potluri, Jalaja, Coutre, Steven, Woyach, Jennifer, Byrd, John C

Volltext

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study von Zinzani, Pier Luigi, Santoro, Armando, Gritti, Giuseppe, Brice, Pauline, Barr, Paul M, Kuruvilla, John, Cunningham, David, Kline, Justin, Johnson, Nathalie A, Mehta-Shah, Neha, Manley, Thomas, Francis, Stephen, Sharma, Manish, Moskowitz, Alison J

Volltext

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy von Jurinovic, Vindi, Kridel, Robert, Staiger, Annette M., Szczepanowski, Monika, Horn, Heike, Dreyling, Martin H., Rosenwald, Andreas, Ott, German, Klapper, Wolfram, Zelenetz, Andrew D., Barr, Paul M., Friedberg, Jonathan W., Ansell, Stephen, Sehn, Laurie H., Connors, Joseph M., Gascoyne, Randy D., Hiddemann, Wolfgang, Unterhalt, Michael, Weinstock, David M., Weigert, Oliver

Volltext

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 von Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Tedeschi, Alessandra, Bairey, Osnat, Bartlett, Nancy L, Burger, Jan A, Hillmen, Peter, Coutre, Steven, Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Li, Jianyong, Simpson, David, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Styles, Lori, James, Danelle, Kipps, Thomas J, Ghia, Paolo

Volltext

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma von Munir, Talha, Brown, Jennifer R., O'Brien, Susan, Barrientos, Jacqueline C., Barr, Paul M., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Kipps, Thomas J., Moreno, Carol, Montillo, Marco, Burger, Jan A., Byrd, John C., Hillmen, Peter, Dai, Sandra, Szoke, Anita, Dean, James P., Woyach, Jennifer A.

Volltext

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology... von Press, Oliver W, Li, Hongli, Schöder, Heiko, Straus, David J, Moskowitz, Craig H, LeBlanc, Michael, Rimsza, Lisa M, Bartlett, Nancy L, Evens, Andrew M, Mittra, Erik S, LaCasce, Ann S, Sweetenham, John W, Barr, Paul M, Fanale, Michelle A, Knopp, Michael V, Noy, Ariela, Hsi, Eric D, Cook, James R, Lechowicz, Mary Jo, Gascoyne, Randy D, Leonard, John P, Kahl, Brad S, Cheson, Bruce D, Fisher, Richard I, Friedberg, Jonathan W

Volltext

Video Recording Policies During Childbirth: An Opportunity to Foster Transparency and Trust von Bratches, Reed W. R., Barr, Paul J.

Volltext